Key result
Shexiang Tongxin Dropping Pills attenuate endothelial inflammation by inhibiting calcium influx and NLRP3 inflammasome activation.
Why the study?
The specific mechanisms by which Shexiang Tongxin Dropping Pills attenuate vascular endothelial inflammation remained incompletely elucidated.
Does Shexiang Tongxin Dropping Pills attenuate vascular endothelial inflammation in LCWE-induced vasculitis models?
Does Shexiang Tongxin Dropping Pills attenuate vascular endothelial inflammation in LCWE-induced vasculitis models?
STDP attenuates vascular endothelial inflammation by targeting the Piezo1/Ca2+/NLRP3 axis, providing a mechanistic basis for its use in cardiovascular disorders.
No immediate role in clinical practice for vascular inflammation; leaves open Piezo1/Ca²⁺/NLRP3 inhibition as hypothesis-generating for human translational studies.
BACKGROUND: Vascular endothelial inflammation is a key pathological process underlying various inflammatory vascular conditions, which can lead to severe cardiovascular complications. Shexiang Tongxin Dropping Pills (STDP) is a traditional Chinese medicine formulation clinically used for cardiovascular disorders and has shown protective effects on the vascular endothelium. However, the specific mechanisms by which STDP attenuates vascular endothelial inflammation remain incompletely elucidated. METHODS: An experimental model of LCWE-induced vasculitis was established by intraperitoneal injection of lactobacillus casei cell wall extract (LCWE) in C57BL/6 mice. The effects of STDP were evaluated through whole blood analysis, EVG staining, and immunofluorescent staining for adhesion molecules (ICAM-1, VCAM-1) and macrophage infiltration. An in vitro endothelial damage model was established by stimulating murine vascular endothelial cells (MVECs) with LCWE. Network pharmacology, calcium imaging, and siRNA-mediated knockdown of Piezo1 were employed to elucidate the underlying mechanism. RESULTS: ) influx. This inhibitory effect prevented the activation of the NLRP3 inflammasome in endothelial cells, thus protecting endothelial cells and alleviating inflammation. CONCLUSION: /NLRP3 pathway may represent a novel therapeutic target for ameliorating vascular endothelial inflammation.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied Vascular endothelial inflammation. Shexiang Tongxin Dropping Pills (STDP) was evaluated on Vascular endothelial inflammation and NLRP3 inflammasome activation. Shexiang Tongxin Dropping Pills attenuated vascular endothelial inflammation by inhibiting calcium influx and preventing NLRP3 inflammasome activation in endothelial cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: